LSD1 inhibitors currently in clinical development for the treatment of hematologic malignancies and solid tumours have been shown to be relatively safe and well tolerated83, suggesting that LSD1 inhibitors (or derived compounds) may be similarly tolerated in people affected by schistosomiasis. This evidence concerns the gene KDM1A and schistosomiasis.